The Clinical Difference Between the Nonfatal Patients and the Fatal Patients With Severe COVID-19

March 4, 2023 updated by: Zhang Jianheng, The First Affiliated Hospital of Guangzhou Medical University

The Clinical Difference Between the Nonfatal Coronavirus Disease 2019 (COVID-19) Patients and the Fatal Cases With Severe COVID-19

To investigate the difference of the difference between the nonfatal Coronavirus Disease 2019 (COVID-19) Patients and the fatal Patients .The cross sectional study was undertaken to compare the clinical information (laboratory and radiologic characteristics)of nonfatal participants and fatal cases. The investigators wish figure out the clinical character of the fatal participants. The result may help the physician to find the fatal patients with COVID-19 more easily. The fatal patients with COVID-19 could be treated early.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
    • Guangdong
      • Guanzhou, Guangdong, China, 520120
        • The First Affiliated Hospital of Guangzhou Medical University
    • Hubei
      • Wuhan, Hubei, China, 430014
        • Hankou Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 100 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

The patients with Coronavirus Disease 2019

Description

Inclusion Criteria:

  • The patients with Coronavirus Disease 2019
  • Positive result on real-time reverse-transcriptase-polymerase-chain-reaction
  • Positive result on chest computed tomography

Exclusion Criteria:

  • No

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Cross-Sectional

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
the nonsevere Coronavirus Disease 2019 Patients
Other: no intervention
no intervention
the severe Coronavirus Disease 2019 Patients
Other: no intervention
no intervention

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Lymphocyte cell
Time Frame: 2 month
the counting of Lymphocyte(counts/L)
2 month
d-dimer
Time Frame: 2 month
d-dimer（mg/L）
2 month
PLT
Time Frame: 2 month
the counting of Platelets（(counts/L)）
2 month
CRP
Time Frame: 2 month
the level of C-reactive protein (mg/uL)
2 month
LDH
Time Frame: 2 month
lactate dehydrogenase ( U/L)
2 month
CK
Time Frame: 2 month
creatine kinase (U/L)
2 month
PT
Time Frame: 2 month
prothrombin time(second)
2 month
ALT
Time Frame: 2 month
alanine aminotransferase(U/L)
2 month
AST
Time Frame: 2 month
aspartate aminotransferase(U/L)
2 month
NK cell
Time Frame: 2 month
natural killer cell(counts/L)
2 month
PCT
Time Frame: 2 month
procalcitonin（ng/ml）
2 month
IL-6
Time Frame: 2 month
interleukin-6(mg/L)
2 month

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
the clinical difference of radiologic characteristics between the fatal patients with COVID -19 and the non fatal cases
Time Frame: 2 months
CT scan feature
2 months

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
SPO2
Time Frame: 2 month
oxygen Saturation
2 month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

The First Affiliated Hospital of Guangzhou Medical University

Investigators

  • Principal Investigator: jianheng zhang, MD, First Afiliated hospital of Guangzhou medical university

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 1, 2020

Primary Completion (Actual)

June 6, 2020

Study Completion (Actual)

June 20, 2020

Study Registration Dates

First Submitted

April 21, 2020

First Submitted That Met QC Criteria

May 24, 2020

First Posted (Actual)

May 27, 2020

Study Record Updates

Last Update Posted (Estimate)

March 7, 2023

Last Update Submitted That Met QC Criteria

March 4, 2023

Last Verified

March 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • YLS2020(112)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

IPD Plan Description

It is not decided

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Coronavirus Disease 2019

Clinical Trials on no intervention

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Portugal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe